유럽 연합 - 스페인어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - neoplasmas prostáticos - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

유럽 연합 - 스페인어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. excepto en recién diagnosticados de lmc en fase crónica, no existen ensayos controlados que demuestran un beneficio clínico o el aumento de la supervivencia para estas enfermedades. .

유럽 연합 - 스페인어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - acetato de abiraterona - neoplasmas prostáticos - terapia endocrina - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

유럽 연합 - 스페인어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - fumarato de dimetilo - multiple sclerosis, relapsing-remitting; multiple sclerosis - inmunosupresores - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

accord healthcare, s.l.u - tadalafilo - excipientes: lactosa monohidrato secada por aspersion,croscarmelosa sodica,estearato de sorbitan tipo ii - otros productos de uso urolÓgico, incluyendo antiespasmÓdicos - fármacos usados en disfunción eréctil - tadalafilo

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

accord healthcare, s.l.u - tadalafilo - excipientes: lactosa monohidrato secada por aspersion,croscarmelosa sodica,sorbitan monoestearato - otros productos de uso urolÓgico, incluyendo antiespasmÓdicos - fármacos usados en disfunción eréctil - tadalafilo

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

accord healthcare, s.l.u - tadalafilo - excipientes: lactosa monohidrato secada por aspersion,croscarmelosa sodica,estearato de sorbitan tipo ii - otros productos de uso urolÓgico, incluyendo antiespasmÓdicos - fármacos usados en disfunción eréctil - tadalafilo

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

accord healthcare, s.l.u - tolterodina tartrato - excipientes: n/a - otros productos de uso urolÓgico, incluyendo antiespasmÓdicos - antiespasmódicos urinarios - tolterodina

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

accord healthcare, s.l.u - tolterodina tartrato - excipientes: n/a - otros productos de uso urolÓgico, incluyendo antiespasmÓdicos - antiespasmódicos urinarios - tolterodina

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

accord healthcare, s.l.u - olmesartan medoxomilo - excipientes: lactosa monohidrato - antagonistas de angiotensina ii, monofÁrmacos - antagonistas de angiotensina ii, monofármacos - olmesartan medoxomilo